Interesting, although perhaps not unsurprisingly?(?) that are new posters here trying to gather info about the share, it sounds like all the talk of T-cells lately seems to have certainly piqued interest.
@symbo1 - I see you frequent the Omega Diagnostics board, a huge Covid riser, are people over there looking for their next Covid play?
So am i right in saying Scancell/Professor Durrant have pretty high billing at this event? Don't want to sign up for the agenda, but judging by the start date/times of the event it looks like Prof. Durrant is actually opening the event with her key note speech?
"SCANCELL Retweeted Immuno Series @ImmunoOncConf · Aug 3 What do you know about Citrullination And Homocitrullination? 2 exciting words in the world of #IO & #personalisedmedicine. Hear more about this exciting area by reg for #immunouk20virtual. @scancellpharma will be presenting live at 9am on 24th August! https://bit.ly/3frKyZm "
I know this AstraZeneca deal was mentioned before, however I never realised it was for up to $6b! And that they had another for $6.9 billion with another company last year...big big numbers.
"AstraZeneca, Daiichi Sankyo sign $6B deal for antibody-drug conjugate The companies will share development and commercialization of DS-1062 in solid tumors. They already have a similar deal in place, the $6.9 billion agreement signed last year for another ADC, the HER2-positive breast cancer drug Enhertu."
"SCANCELL Retweeted Menelas Pangalos @MenePangalos · Aug 1 Great paper for anyone interested in the immune response to SARS-CoV2- highlights the importance of not just neut antibodies but also T cell responses